Delving into the Latest Updates on Mycomedica Life Sciences Pbc with Synapse

概览

疾病领域	数量

神经系统疾病	1
肿瘤	1
免疫系统疾病	1
内分泌与代谢疾病	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

5-HT1A receptor x 5-HT2A receptor x 5-HT2C receptor x 5-HT6 receptor	1

关联

1

项与 Mycomedica Life Sciences Pbc 相关的药物

Psilocybin

裸盖菇素

靶点

5-HT1A receptor x 5-HT2A receptor x 5-HT2C receptor x 5-HT6 receptor

作用机制

5-HT1A receptor拮抗剂 [+3]

在研机构

Compass Pathways Plc [+36]

原研机构-

在研适应症

重度抑郁症 [+48]

非在研适应症

遗忘 [+5]

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

3

项与 Mycomedica Life Sciences Pbc 相关的临床试验

NCT07050368

/ Completed临床1期

A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers

MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions.
The purpose of this trial is to investigate brain activity, safety, tolerability, and PK of multiple doses of MLS101 in healthy participants.

开始日期2025-07-28

申办/合作机构

Mycomedica Life Sciences Pbc

NCT06643637

/ Completed临床1期

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Participants

MLS101 is being developed as a low dose psilocybin, that can be administered to treat neurological and psychiatric conditions.
The purpose of this clinical trial is to assess how safe and tolerated MLS101 is; to see how MLS101 is distributed and cleared by the body (pharmacokinetics); and to assess the psychedelic effects of MLS101 in healthy, adult participants.

开始日期2024-11-08

申办/合作机构

Mycomedica Life Sciences Pbc

NCT06326606

/ Completed临床1期

A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy Participants

MLS101 is being developed as a low dose psilocybin, that can be administered to treat various neurological and psychiatric conditions.
The purpose of this clinical trial is to assess how safe and tolerated MLS101 is; to see how MLS101 is distributed and cleared by the body (pharmacokinetics); and to assess the psychedelic effects of MLS101 in healthy adult participants.

开始日期2024-03-27

申办/合作机构

Mycomedica Life Sciences Pbc

100 项与 Mycomedica Life Sciences Pbc 相关的临床结果

登录后查看更多信息

0 项与 Mycomedica Life Sciences Pbc 相关的专利（医药）

登录后查看更多信息

100 项与 Mycomedica Life Sciences Pbc 相关的药物交易

登录后查看更多信息

100 项与 Mycomedica Life Sciences Pbc 相关的转化医学

登录后查看更多信息